HIF1α-mediated transactivation of WTAP promotes AML cell proliferation via m6A-dependent stabilization of KDM4B mRNA
- PMID: 37087529
- DOI: 10.1038/s41375-023-01904-1
HIF1α-mediated transactivation of WTAP promotes AML cell proliferation via m6A-dependent stabilization of KDM4B mRNA
Abstract
Hypoxia inducible factor 1α (HIF1α) is abnormally overexpressed in t(8;21) acute myeloid leukemia (AML) and functions as an oncogene through transactivating DNA methyltransferase 3 alpha leading to DNA hypermethylation. However, it remains unclear whether HIF1α influences RNA N6-methyladenosine (m6A) methyltransferases. Here, we show that HIF1α promotes the expression of Wilms tumor 1-associated protein (WTAP), a main component of the m6A methyltransferase complex, markedly alters the transcriptome-wide m6A distribution and enhances cell proliferation in t(8;21) AML. In agreement with this, WTAP is overexpressed and predicts poor prognosis in t(8;21) AML patients. Moreover, WTAP knockdown inhibits growth, and induces apoptosis and differentiation of leukemia cells. Mechanistically, HIF1α transactivates WTAP gene expression by directly binding to the hypoxia-response element of its promoter region. Pharmacological or genetic intervention in the HIF1α-WTAP axis results in the reduction of m6A level on lysine demethylase 4B (KDM4B) transcripts and increased its degradation, correlated with lower expression of KDM4B and higher trimethylation levels of histone H3 on lysine 9. KDM4B knockdown inhibits leukemia cell growth in vitro and in mice. Thus, HIF1α-mediated WTAP high expression enhances the malignant behavior of leukemia cells and drives a crosstalk between m6A RNA methylation and histone methylation through monitoring m6A-dependant KDM4B translation.
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m6A methylation of MYC mRNA.J Cancer Res Clin Oncol. 2021 Jan;147(1):33-47. doi: 10.1007/s00432-020-03373-w. Epub 2020 Sep 3. J Cancer Res Clin Oncol. 2021. PMID: 32880751
-
YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.Oncogene. 2021 Jun;40(22):3786-3798. doi: 10.1038/s41388-021-01818-1. Epub 2021 May 6. Oncogene. 2021. PMID: 33958724
-
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.Leukemia. 2015 Aug;29(8):1730-40. doi: 10.1038/leu.2015.56. Epub 2015 Mar 2. Leukemia. 2015. PMID: 25727291
-
Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential.Biomolecules. 2022 Sep 2;12(9):1224. doi: 10.3390/biom12091224. Biomolecules. 2022. PMID: 36139062 Free PMC article. Review.
-
The RNA m6A writer WTAP in diseases: structure, roles, and mechanisms.Cell Death Dis. 2022 Oct 7;13(10):852. doi: 10.1038/s41419-022-05268-9. Cell Death Dis. 2022. PMID: 36207306 Free PMC article. Review.
Cited by
-
RNA modification in normal hematopoiesis and hematologic malignancies.MedComm (2020). 2024 Oct 23;5(11):e787. doi: 10.1002/mco2.787. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39445003 Free PMC article. Review.
-
Elevated WTAP promotes hyperinflammation by increasing m6A modification in inflammatory disease models.J Clin Invest. 2024 May 16;134(14):e177932. doi: 10.1172/JCI177932. J Clin Invest. 2024. PMID: 39007267 Free PMC article.
-
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2.Mol Cancer. 2024 May 31;23(1):116. doi: 10.1186/s12943-024-02013-y. Mol Cancer. 2024. PMID: 38822351 Free PMC article.
-
Small molecule inhibitors targeting m6A regulators.J Hematol Oncol. 2024 May 6;17(1):30. doi: 10.1186/s13045-024-01546-5. J Hematol Oncol. 2024. PMID: 38711100 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical